Follicular lymphoma is a slow-growing cancer of B lymphocytes that is usually controlled for many years rather than cured; NHS and Cancer Research UK state this plainly for advanced disease, while radiotherapy can cure some early-stage cases. About 85% of patients in English registry data live at least five years, and a 2025 review puts 10-year survival after modern immunochemotherapy at about 80%. Personal stories online that claim a cure from diet, herbs or belief are not evidence; this page replaces one of them.
What is follicular lymphoma?
Follicular lymphoma is a slow-growing (indolent) non-Hodgkin lymphoma that begins in B lymphocytes, the white cells that make antibodies. The US National Cancer Institute (NCI) calls it the most common indolent non-Hodgkin lymphoma; it affects lymph nodes and may spread to the bone marrow or spleen, and most patients are 50 or older at diagnosis. Cancer Research UK counts around 2,300 diagnoses a year in the UK, about one in five of all non-Hodgkin lymphomas, mainly in adults over 60.
It is less common in India. A series from JIPMER, Puducherry, published in 2016 found 36 follicular lymphomas among 497 non-Hodgkin lymphomas (7.2%), with a mean age of 50, three men for every woman, and nodal disease in 97% of cases.
The usual sign is a painless swelling in the neck, armpit or groin, where lymphoma cells enlarge a node, according to Macmillan Cancer Support. When the bone marrow is involved it can cause anaemia and easy bruising or bleeding. NCI lists the "B symptoms" that change staging and treatment: fever, drenching night sweats and weight loss. Macmillan says the causes are mostly unknown, a close relative with the disease slightly raises risk, and it is not infectious.
Pathologists grade it 1 to 3. Cancer Research UK explains that grades 1, 2 and 3A behave and are treated as low-grade disease, while grade 3B is treated like a fast-growing (high-grade) lymphoma. Low-grade disease can transform into high-grade lymphoma, sometimes many years after diagnosis.
How is it diagnosed and staged?
A lymph node biopsy makes the diagnosis; no blood test can. Cancer Research UK describes a core needle or excisional biopsy of a swollen node. NCI adds the tissue tests, immunohistochemistry, immunophenotyping, cytogenetics and FISH, which separate follicular lymphoma from other B-cell lymphomas.
Staging then shows how far it has spread. The standard tests are:
- Blood tests: a complete blood count (CBC test prices), blood chemistry, LDH, and hepatitis B, hepatitis C and HIV tests, all listed by NCI.
- PET-CT scan: shows where the lymphoma is (the stage) and later how well treatment has worked (PET scan prices); CT of the chest, abdomen and pelvis shows affected nodes.
- Bone marrow aspiration and biopsy: checks for marrow involvement, which makes the disease stage 4.
NCI's stages: stage 1 is one lymph node group; stage 2 is two or more groups on the same side of the diaphragm; stage 3 is nodes on both sides of the diaphragm or nodes plus spleen; stage 4 is spread to the bone marrow, liver, lungs or another organ.
Cancer Research UK groups stages 1 and 2 as early (limited) and 3 and 4 as advanced, with bulky stage 2 sometimes treated as advanced; in the JIPMER series 72% were stage 3 or 4 at diagnosis.
Doctors also calculate the FLIPI score from age, stage and blood test results, which Cancer Research UK uses to divide patients into low, intermediate and high-risk groups with different survival.
Can follicular lymphoma be cured?
For most people, no: advanced follicular lymphoma is controlled, often for decades, rather than cured. NHS says treatment for low-grade non-Hodgkin lymphoma "does not get rid of it but can keep it under control for many years". Cancer Research UK states that the aim for advanced disease is to control the lymphoma for as long as possible, and that treatment can often control it for several years at a time. Macmillan uses the word remission, meaning control for as long as possible.
Two exceptions matter. First, Cancer Research UK says radiotherapy for early-stage disease can control it for a long time "and may cure it". Second, a 2025 review in Hematological Oncology by Kumar and Okosun describes a "functional cure" after first-line immunochemotherapy for many patients, with 10-year overall survival of about 80%: the disease does not return in their lifetime even though it is not proven eradicated. Even after radiotherapy, the Memorial Sloan Kettering group advises long-term surveillance.
This is why online stories titled "how I cured my follicular lymphoma" are not evidence. A disease that NCI says can shrink or disappear on its own and then return, that is routinely left untreated for years, and that is controlled for a decade or more by standard treatment, will produce many people who feel cured by whatever they were doing at the time. None of the sources cited here reports a cure from diet, supplements, herbs, fasting or alternative medicine, and no such claim should delay a biopsy or a consultation with an oncologist.
What is watch and wait, and why is it safe?
Watch and wait means regular check-ups and blood tests with no treatment until the lymphoma causes symptoms or threatens an organ. Cancer Research UK says it is generally preferred for advanced disease without symptoms, and that the alternative, rituximab alone, is an option; adding chemotherapy at this point only adds side effects. Macmillan notes that some people need no treatment for months or years. NCI explains the logic: follicular lymphoma may go away without treatment, so patients are monitored closely and treated when signs or symptoms appear or return.
NHS describes regular tests during this period, with treatment starting when the tests show it is needed. Cancer Research UK also lists active monitoring for early-stage disease when the biopsy removed all visible disease or radiotherapy is unsuitable.
Watch and wait is hard psychologically, and the 2025 review notes it remains an option for low tumour-burden disease alongside single-agent rituximab. Patients in India sometimes read it as neglect or cost-cutting; it is neither. Cancer Research UK says adding chemotherapy at this stage only adds side effects, and that each remission after a relapse tends to be shorter than the one before, so treatment is saved for when it is needed.
Macmillan describes the alternative as regular check-ups. Ask the haematologist which symptoms should prompt an earlier visit.
What is rituximab-based treatment?
Rituximab-based treatment pairs an anti-CD20 antibody with chemotherapy and is the standard first-line treatment when advanced follicular lymphoma needs treating. Cancer Research UK lists the combinations: rituximab or obinutuzumab with bendamustine, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone), CVP or chlorambucil. Macmillan adds that prednisolone steroid tablets are usually part of CVP or CHOP. The 2025 review names R-CHOP, R-CVP, R-bendamustine and O-CVP as the regimens for symptomatic, high tumour-burden disease, and reports that lenalidomide with rituximab (R2) gave progression-free and overall survival comparable to rituximab-chemotherapy in the RELEVANCE trial.
If the lymphoma goes into remission, Cancer Research UK and Macmillan describe maintenance: rituximab or obinutuzumab roughly every two months for up to two years to delay relapse. The 2025 review is candid that maintenance improves progression-free survival but has not been shown to lengthen overall survival, and that its use varies between centres.
NCI lists further first-line and later options: obinutuzumab with or without chemotherapy, lenalidomide and rituximab, and the EZH2 inhibitor tazemetostat. Before any anti-CD20 antibody, hepatitis B status is checked, since NCI includes hepatitis B and C testing in the work-up.
Ask whether the hospital's package under Ayushman Bharat or a state scheme includes the antibody as well as the chemotherapy.
When is radiotherapy used?
Radiotherapy to the involved lymph nodes is the usual first treatment for stage 1 or limited stage 2 follicular lymphoma, and it is the one setting in which cure is a realistic aim. Cancer Research UK says radiotherapy can control early-stage disease for a long time and may cure it; Macmillan notes that follicular lymphoma is very sensitive to radiotherapy, which can also relieve pain from a pressing node. NCI lists radiation therapy first among options for stage 1 and contiguous stage 2 indolent lymphoma, with rituximab or chemotherapy and watchful waiting as alternatives.
The numbers come from a Memorial Sloan Kettering series of 295 adults with stage 1 or 2 grade 1 to 3A follicular lymphoma, published in Blood Cancer Journal in 2022. Among 108 treated with radiotherapy alone, 5-year overall survival was 98.0% and 5-year progression-free survival 62.3%; across the whole cohort, 10-year overall survival was 87.2%. In other words, most people are alive a decade later, but about a third see the lymphoma return somewhere within five years, which is why the authors caution that long-term surveillance may be needed even after apparently definitive treatment.
The same cohort measured transformation to aggressive lymphoma: 4.2% at five years and 10.8% at ten years. Cancer Research UK says transformed disease is treated like high-grade lymphoma, usually with chemotherapy and rituximab and sometimes a stem cell transplant, and that outcomes have improved.
Low-dose radiotherapy is also used in advanced disease to shrink a painful or obstructing node, which NCI lists as palliative radiation.
What happens if it relapses, and what are the newer options?
Follicular lymphoma usually returns, and each relapse is usually treatable, though Cancer Research UK warns that second and later remissions are typically shorter than the first. Treatment can again be delayed if there are no symptoms. Its listed options are multi-drug chemotherapy with rituximab, a single chemotherapy drug with or without an antibody, rituximab alone, or lenalidomide with rituximab, with radiotherapy for symptomatic nodes. After a second or later relapse, fit patients may be offered high-dose chemotherapy with a stem cell transplant.
The newer options are immune treatments. NCI lists CAR T-cell therapy and the bispecific antibody mosunetuzumab for recurrent indolent lymphoma, alongside tazemetostat and radiolabelled antibodies. Cancer Research UK adds the bispecific epcoritamab after at least two prior treatments. The 2025 review names three approved CAR-T products (axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel) and three CD20xCD3 bispecifics (mosunetuzumab, epcoritamab and odronextamab), and reports that about half of CAR-T recipients remain in long-term remission, while "whether these durable responses equate to potential cure is unclear".
The review says progression within 24 months of first treatment (POD24) affects 10% to 20% of patients and carries worse survival: in one cohort, 5-year overall survival was 31% when POD24 came with transformation and 71% when the relapsed disease was still indolent.
In India, the first home-grown CAR-T therapy for blood cancers, NexCAR19, was launched in April 2024, according to a Press Information Bureau factsheet. Ask about access and clinical trials at a National Cancer Grid centre, listed under hospitals.
What are the survival figures, and how do people live with it?
About 85 in 100 people with follicular lymphoma live at least five years, and the figure depends on the FLIPI risk group. Cancer Research UK, using Haematological Malignancy Research Network data for people diagnosed in one English region in 2010 to 2019, gives 5-year relative survival of almost 100% in the low-risk group, around 90% in the intermediate group and almost 75% in the high-risk group. The US SEER programme reports 5-year relative survival of 74.3% for all non-Hodgkin lymphomas combined (2016 to 2022), from 87.6% at stage 1 to 63.6% at stage 4; follicular lymphoma survival is higher than that all-type average.
| Measure | Figure | Source |
|---|---|---|
| 5-year survival, all follicular lymphoma | About 85% | Cancer Research UK (HMRN, 2010 to 2019) |
| 10-year survival after immunochemotherapy | About 80% | Kumar and Okosun, 2025 review |
| 5-year survival, all NHL | 74.3% | NCI SEER, 2016 to 2022 |
Living with it means long-term follow-up. Macmillan describes regular appointments to check the lymphoma and raise concerns, late effects of treatment that can appear months or years later, and support lines and forums.
See the haematologist within days, not at the next scheduled visit, for a node that grows quickly over weeks, or for fever, drenching night sweats or weight loss; these B symptoms can signal transformation to high-grade lymphoma. In an emergency, call 112.
This guide is general information from the sources listed below, not medical advice; a registered doctor makes decisions with you.
